Premium
Pax‐5 expression in neoplastic mammary cell lines in response to stimulations by estrogen or tamoxifen
Author(s) -
Beaulieu Anick,
Laflamme Mark,
Ouellette Rodney
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.215
Subject(s) - tamoxifen , estrogen , biology , carcinogenesis , cell culture , cancer research , gene expression , stimulation , cell , estrogen receptor , microbiology and biotechnology , breast cancer , endocrinology , cancer , gene , genetics
Pax‐5 is an important contributor to B cell development. Several studies have shown that the deregulated expression of Pax‐5 is implicated in onset of different types of cancers. Previously, we have observed that Pax‐5 expression in B‐cells increases dramatically upon estrogen stimulation, and that Pax‐5 is expressed in breast cancer cell lines while it is undetectable in normal mammary cell lines. Based on this evidence, we hypothesis that Pax‐5 may exercise a key role in mammary oncogenesis and that this abnormal function may be modulated by estrogen. In order to shed light on these initial findings, using quantitative real‐time RT‐PCR we have characterized the Pax‐5 expression profiles in several mammary cell lines following stimulation with estrogen and Tamoxifen. We have found that in each case, Pax‐5 expression is differentially modulated when comparing treated and untreated cells. Further to this, we are using oligonucleotide microarrays to identify the gene expression pathways influenced by the differential Pax‐5 expression in these cell lines. This research is supported by a Canadian Institute of Health Research (RPP) Grant and an Atlantic Innovation Fund Grant to RJO.